Saybrook Capital NC Increases Stock Position in Kenvue Inc. (NYSE:KVUE)

Saybrook Capital NC boosted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 323,480 shares of the company's stock after acquiring an additional 18,783 shares during the period. Kenvue accounts for about 1.8% of Saybrook Capital NC's investment portfolio, making the stock its 15th largest position. Saybrook Capital NC's holdings in Kenvue were worth $6,906,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in KVUE. Concurrent Investment Advisors LLC boosted its stake in shares of Kenvue by 131.9% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 53,517 shares of the company's stock worth $1,238,000 after purchasing an additional 30,438 shares during the last quarter. Graypoint LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth about $233,000. Principal Financial Group Inc. boosted its stake in shares of Kenvue by 3.2% during the 3rd quarter. Principal Financial Group Inc. now owns 2,364,451 shares of the company's stock worth $54,690,000 after purchasing an additional 73,542 shares during the last quarter. CWA Asset Management Group LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth about $307,000. Finally, Galvin Gaustad & Stein LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth about $214,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

KVUE has been the topic of several research analyst reports. UBS Group decreased their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Canaccord Genuity Group raised their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Barclays decreased their target price on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Friday, January 17th. Citigroup decreased their target price on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and decreased their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, Kenvue has an average rating of "Hold" and an average target price of $23.75.

Remove Ads

Kenvue Trading Up 2.0 %

KVUE traded up $0.48 during trading on Monday, hitting $23.90. 18,034,740 shares of the company's stock were exchanged, compared to its average volume of 14,630,980. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a 50 day moving average price of $21.69 and a 200 day moving average price of $22.35. The firm has a market cap of $45.67 billion, a P/E ratio of 45.09, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.43%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.